News about Iterum Therapeutics Plc

Iterum Therapeutics Regains Nasdaq Compliance and Closes Successful Rights Offering, Fueling Growth in Antibiotic Development,
Nov 21 2024
Iterum Therapeutics Regains Full Nasdaq Compliance Amid Successful Rights OfferingIn an inspiring turn of events, Iterum Therapeutics plc (Nasdaq: ITR...

Iterum Therapeutics Completes Successful Rights Offering, Paving the Way for Growth in Shareholder Value
Aug 06 2024
DUBLIN and CHICAGO, Aug. 06, 2024 - Iterum Therapeutics plc (Nasdaq: ITRM), a prominent clinical-stage pharmaceutical company specializing in the...

Iterum Therapeutics Strengthens Market Position with New Patents for Oral Sulopenem
Aug 02 2024
DUBLIN and CHICAGO, Aug. 02, 2024 Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to the advancement of i...

Iterum Therapeutics Launches Rights Offering: A Promising Step Towards Combatting Multi-Drug Resistant Infections
Jul 22 2024
Iterum Therapeutics plc, a clinical-stage pharmaceutical company specializing in the development of advanced oral and IV antibiotics, has re...

Iterum Therapeutics Showcases Groundbreaking Antibiotic Research at ASM Microbe 2024 Conference
Jun 05 2024
Iterum Therapeutics plc, a leading clinical-stage pharmaceutical company specializing in the development of advanced oral and intravenous antibiotics ...

Breaking Boundaries: Iterum Therapeutics Leads the Charge with Oral Sulopenem, Paving the Way for Advanced uUTI Treatment
Apr 29 2024
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem: Bridging the Treatment Gap for uUTIsIterum...

Iterum Therapeutics Overcomes Hurdles, Sets Resubmission of NDA for Sulopenem in Motion
Mar 06 2024
Iterum Therapeutics Provides Business Update: Resubmission of NDA is On Track for First Half of Q2 24Iterum Therapeutics, a renowned pharmaceutical co...

Iterum Therapeutics Plc Reports Impressive Financial Performance in Q3 2023, Showing Promising Progress towards Profitability2.
Nov 16 2023
Iterum Therapeutics Plc Makes Progress in Q3 2023, Investors Optimistic for FutureIterum Therapeutics Plc, a major player in the field of pharmac...